C型慢性肝炎に対するペグインターフェロン/リバビリン併用療法の効果と脂質要因との関係

概要

論文の詳細を見る
It is well known that combination therapy with interferon (IFN) and ribavirin may not achieve the full therapeutic effect in patients with high-titers (≧100 KIU/mL) for hepatitis C virus genotype 1 b. Further, high low-density lipoprotein cholesterol (LDL-C) levels are reported to be a significant indicator of the potential therapeutic effect of IFN in hepatitis C patients, though this is still controversial. In this study, we examined the serum levels of various lipids - comprising LDL-C, total-cholesterol (T-Cho), triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C)-before and after combination therapy with pegylated interferon (PEG-IFN) and ribavirin in chronic hepatitis C patients. In an end of treatment response group (ETR) group, TG levels prior to the start of the therapy were significantly lower than those in a no response (NR) group, while there were no differences in LDL-C, T-Cho and HDL-C levels between the two groups. In a sustained virological response (SVR) group, TG levels were also significantly lower than those of the NR group. These findings suggest that serum TG levels may be a significant predictive factor for the outcome of combined therapy with PEG-IFN and ribavirin in chronic hepatitis C patients.
2008-04-10